- Switzerland
- /
- Life Sciences
- /
- SWX:SFZN
Earnings Miss: Siegfried Holding AG Missed EPS By 6.6% And Analysts Are Revising Their Forecasts
As you might know, Siegfried Holding AG (VTX:SFZN) recently reported its half-year numbers. Siegfried Holding beat revenue expectations by 2.6%, at CHF620m. Statutory earnings per share (EPS) came in at CHF1.49, some 6.6% short of analyst estimates. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
Taking into account the latest results, the consensus forecast from Siegfried Holding's ten analysts is for revenues of CHF1.36b in 2025. This reflects a modest 5.1% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to climb 10% to CHF3.88. Yet prior to the latest earnings, the analysts had been anticipated revenues of CHF1.36b and earnings per share (EPS) of CHF3.47 in 2025. Although the revenue estimates have not really changed, we can see there's been a solid gain to earnings per share expectations, suggesting that the analysts have become more bullish after the latest result.
Check out our latest analysis for Siegfried Holding
The consensus price target was unchanged at CHF112, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Siegfried Holding, with the most bullish analyst valuing it at CHF138 and the most bearish at CHF90.00 per share. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.
Of course, another way to look at these forecasts is to place them into context against the industry itself. The period to the end of 2025 brings more of the same, according to the analysts, with revenue forecast to display 11% growth on an annualised basis. That is in line with its 9.0% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 11% annually. It's clear that while Siegfried Holding's revenue growth is expected to continue on its current trajectory, it's only expected to grow in line with the industry itself.
The Bottom Line
The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Siegfried Holding's earnings potential next year. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. The consensus price target held steady at CHF112, with the latest estimates not enough to have an impact on their price targets.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Siegfried Holding analysts - going out to 2027, and you can see them free on our platform here.
That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Siegfried Holding , and understanding this should be part of your investment process.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SWX:SFZN
Siegfried Holding
Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.
Solid track record with adequate balance sheet.
Similar Companies
Market Insights
Community Narratives


